Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GRK2 | P25098 | 12/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GRK5 | P34947 | 3/20 | 0.34 |
| ▸ | GRK3 | P35626 | 3/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180294 | 0.78 | NPSR1 (0.43) | NPSR1GRK2HTTMAPTCDK5 | |
| SCHEMBL1180296 | 0.78 | NPSR1 (0.43) | NPSR1GRK2HTTMAPTCDK5 | |
| SCHEMBL10613416 | 0.72 | SLC22A1 (0.57) | NPSR1MAOBHTTLMNAGAA | |
| SCHEMBL11887770 | 0.72 | SLC22A1 (0.57) | NPSR1MAOBHTTLMNAGAA | |
| SCHEMBL2416474 | 0.70 | APLNR (0.30) | MAOB | |
| SCHEMBL5258144 | 0.69 | NPSR1 (0.34) | NPSR1HTTMAPTCDK5CDK5R1 | |
| SCHEMBL320672 | 0.69 | ALDH1A1 (0.52) | NPSR1GRK2HTTMAPTCDK5 | |
| SCHEMBL14625071 | 0.69 | NPSR1 (0.34) | NPSR1HTTMAPTCDK5CDK5R1 | |
| SCHEMBL16856782 | 0.65 | GAA (0.40) | NPSR1CDK2GAA | |
| SCHEMBL18971594 | 0.65 | CDK2 (0.36) | NPSR1CDK2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| WO-2007008942-A2 | PHENYLAMINO-ACETIC ACID [1-(PYRIDIN-4-YL)-METHYLIDENE]-HYDRAZIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF G PROTEIN-COUPLED RECEPTOR KINASES FOR THE TREATMENT OF EYE DISEASES | AERIE PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135499-A1 | Hydrazide compounds | GRK4, GRK2, GRK1 | NPSR1 769/4885MAOB 1566/4885GRK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.